Fatty liver diseases, bile acids, and FXR - Wikidata - awgldk - TriplyDB

Fatty liver diseases, bile acids, and FXR

Fatty liver diseases, bile acids, and FXR

http://www.wikidata.org/entity/Q28068199

about

Study on the value of serum miR-106b for the early diagnosis of hepatocellular carcinoma.An estrogen receptor β-selective agonist inhibits non-alcoholic steatohepatitis in preclinical models by regulating bile acid and xenobiotic receptors.The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.Gut-Liver Axis Derangement in Non-Alcoholic Fatty Liver Disease Remote Sensing between Liver and Intestine: Importance of Microbial Metabolites.Role of FXR in Liver Inflammation during Nonalcoholic Steatohepatitis.FXR deletion in hepatocytes does not affect the severity of alcoholic liver disease in mice FXR and TGR5 Agonists Ameliorate Liver Injury, Steatosis, and Inflammation After Binge or Prolonged Alcohol Feeding in Mice Effects of resveratrol, exercises and their combination on gene expression and apoptosis in the liver of elderly rats with nonalcoholic fatty liver

P2860

Q33740486-154E0694-0CF7-49F1-86F2-39ECCA816B29 Q39018492-47207640-3B05-424E-86E5-88DF4774D9EB Q39262148-2D1BA562-92F3-4FE6-90A7-31B993695FF7 Q41552497-339A7970-C8A7-4763-AA48-DFCA91BE782F Q49569061-60485C4A-081E-4CCA-BA0B-E5692EFA568C Q49569072-7D3D64B0-7D29-4965-9EDC-F025C1D40833 Q57106885-6F4FD734-C7E1-4D18-BEEE-AEB9C9624E23 Q58562856-72CB3509-35DC-4EAF-B7BA-3E61510B633C Q58754705-DA674200-E0D0-436E-B9F0-945269ADEA65

P2860

Fatty liver diseases, bile acids, and FXR

http://www.wikidata.org/entity/Q28068199

description

2016 nî lūn-bûn

@nan

2016 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Fatty liver diseases, bile acids, and FXR

@ast

Fatty liver diseases, bile acids, and FXR

@en

Fatty liver diseases, bile acids, and FXR

@nl

type

label

Fatty liver diseases, bile acids, and FXR

@ast

Fatty liver diseases, bile acids, and FXR

@en

Fatty liver diseases, bile acids, and FXR

@nl

prefLabel

Fatty liver diseases, bile acids, and FXR

@ast

Fatty liver diseases, bile acids, and FXR

@en

Fatty liver diseases, bile acids, and FXR

@nl

P1433

Q28068199-E64F93D5-F33F-4237-A8C9-4842B5A500D7

P1476

Q28068199-F208280C-4152-4B79-98CD-574191D922CC

P2093

Q28068199-131DD958-7B6A-4BAC-88E8-C1010C5DBAB6

Q28068199-1C823447-EE90-48A5-881B-EF77A1F2C07E

Q28068199-88A927D8-F0B3-4AED-898D-2E407A71B618

Q28068199-DC0E8909-D31A-4556-9996-0DDF91A51857

P2860

Q28068199-01CDA618-0F6B-4D80-B0FB-C8644A5EDC7D

Q28068199-0A3C6AD0-3E89-4AAB-B41D-151E12DFEE17

Q28068199-103DA9AE-66F6-4FE6-A8A9-CA502C964C82

Q28068199-11F21097-E4C7-4B04-8ACF-971C5333298F

Q28068199-13471212-8556-411B-96FF-F0A0F7036FB0

Q28068199-15C5647F-9198-4943-86EF-88BDF0713AF0

Q28068199-18B4CB7E-CB09-4903-833A-7EB0AE0B7B8C

Q28068199-18B793FF-1B52-4941-AD44-A45965272AD5

Q28068199-1C2C2A0E-5A07-41BF-B5DF-1D81D3042018

Q28068199-209D4056-AA00-41AA-9D86-BB69C8BB5288

P304

Q28068199-E37BEC23-CA24-4B0E-8B2C-D68E4F3459BD

P31

Q28068199-B375806F-A7A3-4AC7-8D8A-0A8A837570BB

P3181

Q28068199-D4D52E5D-03AD-45AC-A9B8-59EECE176E18

P356

Q28068199-4887E147-492E-427F-B031-6210A2DB1E64

P407

Q28068199-CBFFEF89-A5A1-42CA-9AF5-3AC3F331F3FE

P433

Q28068199-41C6D117-D1EB-4B27-B334-659542203596

P478

Q28068199-29F348F5-ACA7-4E92-AF68-B82B09E88810

P577

Q28068199-61AF3A0D-E7AE-4263-B63B-F7BF54242BDC

P698

Q28068199-3A72F990-21B6-45C7-90AA-CD854F443391

P921

Q28068199-1343a71a-4897-2918-15ee-556c1be7a256

P932

Q28068199-09B3CF17-C4F0-480B-AE1C-E12502B6FA3B

P3181

P356

J.APSB.2016.07.008

P1433

Acta pharmaceutica Sinica B

P1476

Fatty liver diseases, bile acids, and FXR

@en

P2093

Grace L. Guo

http://www.w3.org/2001/XMLSchema#string

Hongxia Liu

http://www.w3.org/2001/XMLSchema#string

Min Zhang

http://www.w3.org/2001/XMLSchema#string

Yan Zhu

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of a nuclear receptor for bile acids

Bile acids: natural ligands for an orphan nuclear receptor

Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression

Bile salts of vertebrates: structural variation and possible evolutionary significance

Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease

Endogenous bile acids are ligands for the nuclear receptor FXR/BAR

Human kininogen gene is transactivated by the farnesoid X receptor

Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine

Identification of a nuclear receptor that is activated by farnesol metabolites

The farnesoid X-receptor is an essential regulator of cholesterol homeostasis

P304

409-412

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4118119

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.APSB.2016.07.008

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2016-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27709009

http://www.w3.org/2001/XMLSchema#string

P921

fatty liver disease

P932

5045552

http://www.w3.org/2001/XMLSchema#string